In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

EHJ - Cardiovascular Pharmacotherapy

Specific focus on clinical cardiovascular pharmacology


The European Heart Journal - Cardiovascular Pharmacotherapy (EHJ-CVP) is the official journal of the European Society of Cardiology and the ESC Working Group on Cardiovascular Pharmacotherapy. The journal aims to improve the pharmacological treatment of patients with cardiovascular disease through interpreting and integrating new scientific developments within this area.

It publishes original articles concerning clinical research, with new and established drugs and methods, as well as meta-analysis and topical reviews.


Fast Facts

  • Editor-in-Chief: Stefan Agewall FESC, NO
  • Current volume: 5 (year 2019)
  • Issues per subscription: 4
Updates on latest articles

Updates on latest articles


Receive Table of contents in your mailbox.

Track the topics, authors and articles important to you and receive articles in your mailbox.

For Authors

Before being published, all manuscripts go through double-blinded peer review by experienced international experts.

Most recent articles from EHJ-CVP

07 Jan 2019
Old and new drugs in cardiovascular pharmacotherapy
Author(s):Agewall S.
29 Nov 2018
CABANA trial: disappointing results?
Author(s):De Vecchis R.
05 Dec 2018
Corrigendum to: Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review
17 Oct 2018
Corrigendum to: ESC Council on hypertension position document on the management of hypertensive emergencies